Bortezomib as a potential treatment for prostate cancer

被引:107
作者
Papandreou, CN [1 ]
Logothetis, CJ [1 ]
机构
[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
关键词
D O I
10.1158/0008-5472.CAN-03-2707
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Androgen ablation and chemotherapy provide effective palliation for most patients with advanced prostate cancer, but eventually progressing androgen-independent prostate cancer threatens the lives of patients usually within a few years, mandating improvement in therapy. Proteasome inhibition has been proposed as a therapy target for the treatment of solid and hematological malignancies. The proteasome is a ubiquitous enzyme complex. that is a hub for the regulation of many intracellular regulatory pathways; because of its essential function, this enzyme has become a new target for cancer treatment. Studies with bortezomib (VELCADE, formerly known as PS-341) and other proteasome inhibitors indicate that cancer cells are especially dependent on the proteasome for survival, and several mechanisms used by prostate cancer cells require proteasome function. Bortezomib has been studied extensively in vitro and in vivo, and anticancer activity has been seen in cell and animal models for several solid tumor types, including prostate cancer. A Phase I trial to determine the maximum tolerated dose of once-weekly bortezomib has been completed. This trial included a large fraction of patients with androgen-independent prostate cancer. The maximum tolerated dose was reached at 1.6 mg/m(2). A correlation was seen among bortezomib dose, proteasome inhibition, and positive modulation of serum prostate-specific antigen. There was also evidence of down-regulation of serum interleukin 6, a downstream nuclear factor kappaB effector. This Phase I trial and preclinical studies support additional testing of bortezomib in combination with radiation or chemotherapy for androgen-independent prostate cancer.
引用
收藏
页码:5036 / 5043
页数:8
相关论文
共 115 条
[31]  
Feinman R, 2001, BLOOD, V98, p368A
[32]  
Frankel A, 2000, CLIN CANCER RES, V6, P3719
[33]  
Fribourg AF, 2000, CELL GROWTH DIFFER, V11, P361
[34]   Androgen receptor phosphorylation - Regulation and identification of the phosphorylation sites. [J].
Gioeli, D ;
Ficarro, SB ;
Kwiek, JJ ;
Aaronson, D ;
Hancock, M ;
Catling, AD ;
White, FM ;
Christian, RE ;
Settlage, RE ;
Shabanowitz, J ;
Hunt, DF ;
Weber, MJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (32) :29304-29314
[35]  
Goy A, 2003, BLOOD, V102, p180A
[36]   Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression [J].
Graff, JR ;
Konicek, BW ;
McNulty, AM ;
Wang, ZJ ;
Houck, K ;
Allen, S ;
Paul, JD ;
Hbaiu, A ;
Goode, RG ;
Sandusky, GE ;
Vessella, RL ;
Neubauer, BL .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (32) :24500-24505
[37]   Androgen receptor signaling in androgen-refractory prostate cancer [J].
Grossmann, ME ;
Huang, HJ ;
Tindall, DJ .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (22) :1687-1697
[38]  
Gumerlock PH, 2001, CLIN CANCER RES, V7, p3809S
[39]   Adhesion to fibronectin via β1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR) [J].
Hazlehurst, LA ;
Damiano, JS ;
Buyuksal, I ;
Pledger, WJ ;
Dalton, WS .
ONCOGENE, 2000, 19 (38) :4319-4327
[40]   Prostate carcinoma cell death resulting from inhibition of proteasome activity is independent of functional Bcl-2 and p53 [J].
Herrmann, JL ;
Briones, F ;
Brisbay, S ;
Logothetis, CJ ;
McDonnell, TJ .
ONCOGENE, 1998, 17 (22) :2889-2899